These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29077044)

  • 1. Inhibition of Human Kallikrein 5 Protease by Triterpenoids from Natural Sources.
    Matsubara Y; Matsumoto T; Koseki J; Kaneko A; Aiba S; Yamasaki K
    Molecules; 2017 Oct; 22(11):. PubMed ID: 29077044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
    Coda AB; Hata T; Miller J; Audish D; Kotol P; Two A; Shafiq F; Yamasaki K; Harper JC; Del Rosso JQ; Gallo RL
    J Am Acad Dermatol; 2013 Oct; 69(4):570-7. PubMed ID: 23871720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.
    Lee JB; Bae SH; Moon KR; Na EY; Yun SJ; Lee SC
    Exp Dermatol; 2016 Dec; 25(12):956-961. PubMed ID: 27315464
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Roh KB; Ryu DH; Cho E; Weon JB; Park D; Kweon DH; Jung E
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U; Wu Z; Schröder JM
    PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin.
    Kanada KN; Nakatsuji T; Gallo RL
    J Invest Dermatol; 2012 May; 132(5):1435-42. PubMed ID: 22336948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity.
    Zhu Y; Underwood J; Macmillan D; Shariff L; O'Shaughnessy R; Harper JI; Pickard C; Friedmann PS; Healy E; Di WL
    J Allergy Clin Immunol; 2017 Nov; 140(5):1310-1322.e5. PubMed ID: 28238749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
    Eissa A; Amodeo V; Smith CR; Diamandis EP
    J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes.
    Sakabe J; Yamamoto M; Hirakawa S; Motoyama A; Ohta I; Tatsuno K; Ito T; Kabashima K; Hibino T; Tokura Y
    J Biol Chem; 2013 Jun; 288(24):17179-89. PubMed ID: 23629652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorogenic Acid Isomers Isolated from
    Roh KB; Jang Y; Cho E; Park D; Kweon DH; Jung E
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid.
    Morizane S; Yamasaki K; Kabigting FD; Gallo RL
    J Invest Dermatol; 2010 May; 130(5):1297-306. PubMed ID: 20090765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes.
    Kim J; Kim MG; Jeong SH; Kim HJ; Son SW
    Exp Dermatol; 2022 Feb; 31(2):223-232. PubMed ID: 34378233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
    Di Paolo CT; Filippou PS; Yu Y; Poda G; Diamandis EP; Prassas I
    Clin Chem Lab Med; 2019 Oct; 57(11):1737-1743. PubMed ID: 31129650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.
    Thibaut de Ménonville S; Rosignoli C; Soares E; Roquet M; Bertino B; Chappuis JP; Defoin-Platel/Chaussade C; Piwnica D
    Dermatol Ther (Heidelb); 2017 Jun; 7(2):213-225. PubMed ID: 28243927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
    J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
    J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.
    Ramesh K; Matta SA; Chew FT; Mok YK
    Allergy; 2020 Feb; 75(2):403-411. PubMed ID: 31407378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
    de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
    Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.